[Development of empirical treatment guidelines in febrile neutropenic patients on the basis of the Korean data]

Lee DG, Kim SH, Kim SY, Min CG, Park WB, Park YJ, Song YG, Jang JS, Jang JH, Jin JR, Choi JH, Kim CJ, Nam MH, Park JA
Record ID 32014000416
Korean
Original Title: 국내 자료를 근거로 한 호중구감소성 발열 환자의 경험적 치료지침 개발
Authors' recommendations: A treatment guideline development committee was organized under the initiative of the National Evidence-based Healthcare Collaborating Agency with a methodology specialist and experts recommended by 8 academic societies: the Korean Society of Infectious Diseases, Korean Society for Immunocompromised Host Infections, Korean Cancer Association, Korean Society of Clinical Microbiology, Korean Society of Blood and Marrow Transplantation, Korean Society of Hematology, Korean Society for Chemotherapy, and Korean Association for Clinical Oncology. The key questions were selected from the areas of the definition of neutropenic fever, the initial evaluation and the infection risks, antibiotic prophylaxis, initial antibiotic therapy for febrile neutropenic patients, re-evaluation after 3-5 days and change of antibiotics, the use of glycopeptide, catheter-related infections in febrile neutropenic patients, and the use of antifungal agents. Agreement was reached through a systematic review of the literature and discussion in a subcommittee.
Details
Project Status: Completed
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: South Korea
MeSH Terms
  • Practice Guideline
  • Korea
Contact
Organisation Name: National Evidence-based healthcare Collaborating Agency
Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.
Contact Name: int@neca.re.kr
Contact Email: int@neca.re.kr
Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.